Improving Heart Function

What is the optimal timing for mitral valve repair?

Alexandre Mebazaa and Sabine Bleiziffer discuss what "early" repair really means in the management of mitral regurgitation.
As treatment options continue to evolve, determining the right moment to intervene is becoming increasingly important to improve patient outcomes and prevent disease progression.

Watch the 2026 full case-based session to hear expert perspectives on the timing of intervention and the role of multidisciplinary decision-making in mitral regurgitation management.

Learn more: https://brnw.ch/21x313B

🫀Atypical HFrEF: when is the right time to transition from medical therapy to device implantation?

Christophe Leclercq and Gianluigi Savarese share key discussion points from one of the sessions, based on a complex clinical case of atypical HFrEF.

During this session, the expert panel discussed how managing patients with non-ischaemic dilated cardiomyopathy often requires navigating a complex decision-making process between escalating guideline-directed medical therapy (GDMT) and considering cardiac implantable electronic devices (CIEDs).

👉 Watch the full session replay: https://brnw.ch/21x2gH2

🔍 From PVCs to cardiomyopathy: identifying recovery factors

In this 2026 interview, Shelley Zieroth and José Luis Merino explore the complex relationship between premature ventricular contractions and cardiomyopathy. The discussion highlights how ECG characteristics, imaging findings, and overall clinical context contribute to identifying patients most likely to recover after PVC suppression.

🔗 Watch the full replay session:
https://www.iheartfunction.com/cases-resources/pvcs-heart-failure-what-medically-treat-ablate-or-leave-alone

🔎 How to find the right time for the right patient regarding mitral regurgitation in HFrEF?

Alexandre Mebazaa and Michael Boehm walk us through the key challenges in M-TEER, where determining the best indicators and optimal timing for intervention remains one of the most complex challenges in clinical practice.
From 2026, this case-based course session on "Mitral regurgitation - Finding the right time for the right patient - How soon is now?" discussed the challenges of Guideline-Directed Medical Therapy (GDMT) optimisation, the role of percutaneous mitral valve repair (M-TEER), and the critical timing for intervention.

🎥 Learn more with the full session replay: https://brnw.ch/21x1Nuy

🔎 Why does treating aortic stenosis require more than valve intervention alone?

In this interview from 2026, Izabella Uchmanowicz and Sergio Raposeiras Roubín share their key learnings from the course session on "Integrated Care in Aortic Stenosis and HFrEF: From Medical Therapy to Percutaneous Intervention." They explain that even after successful TAVI, patients may continue to face residual heart failure risk linked to underlying myocardial involvement and emphasize the importance of a holistic and multidisciplinary approach to ensure long-term adherence, patient safety, and improved outcomes after TAVI.
🎥 Watch the full session replay: https://brnw.ch/21x1Gnx

📈 The recently published DARE-AF trial in Circulation explored whether the SGLT2 inhibitor Dapagliflozin can reduce the recurrence of atrial fibrillation (AFib) following ablation in patients lacking conventional indications for the medication.

While earlier observational studies involving patients with comorbidities such as heart failure or type 2 diabetes hinted at a potential protective effect against AFib recurrence, the DARE-AF study specifically targeted a distinct cohort: 200 patients scheduled for ablation who did not have diabetes, heart failure, or chronic kidney disease (CKD).

In this Journal Club video, Shelley Zieroth examines the trial's findings and their implications for the use of SGLT2 inhibitors in emerging patient populations.

🔗 [Watch the video](https://brnw.ch/21x1v0i)